Societal value of disease modifying therapy for Alzheimer’s disease
Most health technology assessment (HTA) bodies measure treatment value as benefits from reduced patient morbidity and mortality and weigh these health gains against incremental changes in treatment cost. The limitation of this approach, however, is that it may ignore broader societal value. For instance, if patients have improved functional status, caregiver time and cost burden…